MPP is a joint venture partnership between the McLaren Healthcare System and our Physician members. Our focus is on providing resources to physician offices which provide value and assist with engagement, clinical integration, contracting and quality.
We are dedicated to our members’ success. It is the reason why our physicians are Michigan’s leaders in care and excellence. Experience the many benefits of MPP membership.
MPP is responsible for the negotiation, development and administration of a variety of managed care contracts for our network of physicians, ancillary facilities and hospitals. We serve as a liaison between the McLaren Healthcare System, health plans, employers, physicians, and patients.
September 15, 2021
Renin Angiotensin Aldosterone System Inhibitors (ACE-I and ARB)
BACKGROUND:
ACE cleaves C-terminal peptides on angiotensin I, converting it to angiotensin II, and thus increases blood pressure in two ways: vasoconstriction and stimulation of the release of aldosterone, which increases the retention of water and sodium. ACE-I, ARB’s and DRI’s block this process.
ACE Inhibitors
Angiotensin II Receptor Blockers (ARBs)
benazepril (Lotensin)
candesartan (Atacand)
captopril (Capoten)
eprosartan (Tevetan)
enalapril (Vasotec)
irbesartan (Avapro)
fosinopril (Monopril)
losartan (Cozaar)
lisinopril (Prinivil, Zestril)
olmesartan (Benicar)
perindopril (Aceon)
telmisartan (Micardis)
quinapril (Accupril)
valsartan (Diovan)
ramipril (Altace)
trandolapril (Mavik)
Direct Renin Inhibitor: aliskiren (Tekturna)
DISCUSSIONS:
CONCERNS:
Considering that angiotensin receptor blockers and ACE inhibitors (ACEIs) are purported to upregulate the expression of ACE2 in animal studies, there may be a concern about whether these drugs may increase COVID-19 susceptibility and severity. ACE inhibitors and ARBs do not act on ACE2, the protein that acts as a SARS-CoV-2 receptor, and treatment with ACE inhibitors or ARBs does not appear to result in increased ACE2 expression.1
References: